0.5 mg Conbercept Intravitreal Injection

BIOLOGICAL2 trials

Sponsors

Chengdu Kanghong Biotech Co., Ltd.

Conditions

Neovascular Age-related Macular Degeneration

Phase 3

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

TerminatedNCT03577899

Chengdu Kanghong Biotech Co., Ltd.Neovascular Age-related Macular Degeneration

Start: 2018-09-25End: 2021-05-19Updated: 2021-06-24

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

TerminatedNCT03630952

Chengdu Kanghong Biotech Co., Ltd.Neovascular Age-related Macular Degeneration

Start: 2018-12-21End: 2021-05-19Updated: 2021-06-23